Remicade vs Entyvio
Infliximab vs Vedolizumab · Comparison Guide
Quick Comparison
| Feature | Remicade | Entyvio |
|---|---|---|
| Generic Name | Infliximab | Vedolizumab |
| Manufacturer | Janssen | Takeda |
| Drug Class | TNF-alpha Inhibitor | Anti-integrin |
| Shared Conditions | Crohn's Disease, Ulcerative Colitis | |
Key Differences: Remicade vs Entyvio
For IBD, both are effective but Entyvio is gut-selective (only blocks gut-specific white blood cell trafficking) while Remicade provides systemic TNF inhibition. The VARSITY trial showed Entyvio superior to Humira (not Remicade) for UC. Remicade has rapid onset and is often used as an induction therapy. Entyvio's gut-selective mechanism makes it attractive for older patients or those with infection concerns. Both are given by IV infusion.
💊 Remicade (Infliximab)
- Class: TNF-alpha Inhibitor
- Manufacturer: Janssen
- Full Remicade information →
💊 Entyvio (Vedolizumab)
- Class: Anti-integrin
- Manufacturer: Takeda
- Full Entyvio information →
For IBD, both are effective but Entyvio is gut-selective (only blocks gut-specific white blood cell trafficking) while Remicade provides systemic TNF inhibition. The VARSITY trial showed Entyvio superior to Humira (not Remicade) for UC. Remicade has rapid onset and is often used as an induction therapy. Entyvio's gut-selective mechanism makes it attractive for older patients or those with infection concerns. Both are given by IV infusion.
Neither Remicade nor Entyvio is universally better — the right choice depends on your specific condition, disease severity, insurance formulary, and health history. Your prescriber will determine which is most appropriate based on your clinical situation. BiologicHealthPlus carries both and can help you compare your coverage and costs for either medication.
Switching between biologics is common. Your prescriber will evaluate your current treatment response and determine if a switch is appropriate. BiologicHealthPlus can coordinate the transition including prior authorization for your new medication.
Both Remicade and Entyvio are covered by most commercial insurance plans, Medicare Part D, and Medicaid with prior authorization. BiologicHealthPlus handles insurance verification and prior authorization for both medications at no charge. Most insured patients pay $0–$35/month through manufacturer copay programs.
Remicade and Entyvio both have high cash list prices ($4,000–$9,000/month range) but most commercially insured patients pay $0–$35/month through manufacturer savings programs. BiologicHealthPlus automatically enrolls every patient in all available savings programs at no charge.
✅ BiologicHealthPlus Carries Both Remicade and Entyvio
We handle insurance verification, prior authorization, copay enrollment, and free cold-chain delivery for both medications. Contact us and we'll help you understand your options and costs.
Medical Disclaimer: This comparison is for educational purposes only. The choice between Remicade and Entyvio should be made by your healthcare provider based on your specific medical history, disease severity, and individual circumstances. Last updated: July 2026.